Aetion

Lovell Minnick Partners Appoints Marshall Lux and Robert Orefice to Advisory Council

Retrieved on: 
Thursday, March 14, 2024
Professional Services, Finance, BCG, Aetion, Risk management, Growth, Private equity, Flagstar, Princeton University, Advisory Council, Risk, Health, Financial services, Harvard Business School, WebMD, Computer engineering, Walden University, LMP, Lovell Minnick Partners, AMD, Investment, Partnership, McKinsey & Company, Rochester Institute of Technology, Computer, Economics, Chase

Lovell Minnick Partners (“LMP”), a private equity firm investing in growth-oriented companies, today announced the appointment of Marshall Lux and Robert Orefice to its Advisory Council.

Key Points: 
  • Lovell Minnick Partners (“LMP”), a private equity firm investing in growth-oriented companies, today announced the appointment of Marshall Lux and Robert Orefice to its Advisory Council.
  • Marshall Lux brings over 35 years of experience and most recently served as Senior Partner at BCG and McKinsey, where he focused on all manner of Financial Services and Private Equity.
  • Marshall also serves as an independent member of various Boards, including Mphasis, Flagstar and Guardian Life Mutual Funds.
  • "We are excited to welcome Marshall and Robert as the newest members of our Advisory Council,” says Steve Pierson, Managing Partner at LMP.

Jennifer Rider Appointed ConcertAI Head of Real-World Evidence Services

Retrieved on: 
Tuesday, January 30, 2024
Real-World Evidence, Abstract, Interview, Oncology, Research, AI, Clinical Cancer Research, Public, Flexner Report, FDA, Publication, Public health, Aetion, RCT, RWE, Harvard University, Epidemiology, MPH, Doctor of Science, Harvard Medical School, Drug development, Health, Doctor of Philosophy, University, University of Wisconsin–Madison, RWD

CAMBRIDGE, Mass., Jan. 30, 2024 /PRNewswire/ -- ConcertAI, the leader in oncology Real-World Data (RWD) and AI SaaS Solutions and for healthcare and life sciences, today announced Jennifer Rider, ScD, MPH, as the leader of the company's Real-World Evidence Services, focusing on regulatory applications of RWD as part of registration trials, breakthrough designation solutions post-approval studies, and regulatory registries. 

Key Points: 
  • Dr. Rider has over 20 years of experience in cancer epidemiology and real-world evidence research.
  • She first joined ConcertAI in 2020, moving from there to lead Aetion's Oncology Center of Excellence.
  • "Real-world evidence has taken on a more formal role in regulatory decision-making with the FDA's formalization of their guidance late last year ," said Jeff Elton, PhD, CEO of ConcertAI.
  • To hear more from Jennifer directly, listen to her interview on the latest episode of The ConcertAI Podcast here .

Clearway Health Expands Leadership Team with Robert Voreyer as Chief Financial Officer

Retrieved on: 
Tuesday, November 7, 2023
Health, MBA, Aetion, Growth, COVID, Hospital, CFO, Agriculture, MS, Management

BOSTON, Nov. 7, 2023 /PRNewswire/ -- Robert Voreyer, MBA, has been named chief financial officer of Clearway Health , a specialty pharmacy accelerator partnering with hospitals and health systems to build and strengthen medication access.

Key Points: 
  • BOSTON, Nov. 7, 2023 /PRNewswire/ -- Robert Voreyer, MBA, has been named chief financial officer of Clearway Health , a specialty pharmacy accelerator partnering with hospitals and health systems to build and strengthen medication access.
  • Robert Voreyer, MBA, has been named chief financial officer of Clearway Health, a specialty pharmacy accelerator.
  • "Clearway Health's substantial growth, commitment to enhancing access to lifesaving medications and joining such a high-caliber team committed towards strengthening equitable and quality care for all, are what drew me to this company," said Voreyer.
  • Voreyer also founded a boutique advisory firm, Spencer Holt Advisors, focused on solving financial, operational, and strategic challenges for clients in clean tech, health tech, agriculture and financial services.

PicnicHealth Announces Three New Advisors and Expands Expertise in Regulatory-ready Research

Retrieved on: 
Monday, November 6, 2023
Software, Research, Professional Services, Pharmaceutical, Data Management, Oncology, Consumer, Technology, Data Analytics, Science, Other Consumer, Biotechnology, Health, Food, Johns Hopkins University, Public health, Life, Registry, Merck, Brody, Acquisition, Regulation of tobacco by the U.S. Food and Drug Administration, Harvard University, Professional degrees of public health, Aetion, UnitedHealth Group, University of North Carolina at Pembroke, Cerner Enviza, Faculty of Management Studies – University of Delhi, Disease, Medicine, Health policy, University, Public, Harvard T.H. Chan School of Public Health, Cancer, Center for Drug Evaluation and Research, Health policy and management, Doctor of Philosophy, IQVIA, Pharmaceutical industry, Management, Psychology, Pharmacovigilance, New York University, Epidemiology

PicnicHealth , a leading patient-centered healthcare evidence generation company, appointed three advisors in clinical research design – Nancy Dreyer, Solomon Iyasu, and Jeremy Brody.

Key Points: 
  • PicnicHealth , a leading patient-centered healthcare evidence generation company, appointed three advisors in clinical research design – Nancy Dreyer, Solomon Iyasu, and Jeremy Brody.
  • These new advisors are joining PicnicHealth in an advisory capacity to support the company’s expansion into regulatory use cases.
  • Dr. Dreyer is an internationally recognized expert in the use of real-world evidence for regulatory purposes.
  • Dr. Dreyer holds a Ph.D. in epidemiology and Master of Public Health from the University of North Carolina, Chapel Hill.

B. Braun of America Appoints Two Global Healthcare Leaders to its Board of Directors

Retrieved on: 
Friday, October 27, 2023
Knowledge, Digital, Africa/Harvard School of Public Health Partnership for Cohort Research and Training, Associate, Public health, Industrial engineering, Hannover Medical School, Siemens Healthineers, Lewis Galoob Toys, Inc. v. Nintendo of America, Inc., Financial Oversight and Management Board for Puerto Rico, Doctor of Philosophy, MBA, Human biology, Digital Science, Aetion, McGill University, Biostatistics, Real, Boehringer Ingelheim, Retirement, MS, University, Master of Science, Pain management, Institute of technology, Management, Alphabet, Pharmacoepidemiology, Epidemiology

BETHLEHEM, Pa., Oct. 27, 2023 /PRNewswire/ -- B. Braun of America Inc., a leader in smart infusion therapy and pain management, today announced the appointment of two new members to the company's board of directors. The appointments come as the company strengthens its focus on innovation, data and technology to deliver more tailored therapies and solutions to help healthcare providers improve patient outcomes.

Key Points: 
  • The appointments come as the company strengthens its focus on innovation, data and technology to deliver more tailored therapies and solutions to help healthcare providers improve patient outcomes.
  • Dorothee Bartels, PhD, MSc, is a global business and scientific leader with extensive experience using data analytics to improve healthcare outcomes.
  • Dr. Bartels currently serves as Chief Digital Officer at Aetion, a global leader in healthcare analytics.
  • "We are pleased to welcome these accomplished global business leaders to B. Braun of America's board," said Jean-Claude Dubacher, Chairman and Chief Executive Officer.

Synthetic Data Summit 2023 highlights progress, practical applications, and potential of synthetic health data

Retrieved on: 
Thursday, October 19, 2023
Replica, United Kingdom, Synthetic data, SDG, SVP, Medicine, University of Ottawa, Summit, Aetion, Savoy Place, Canada Research Chair in International Political Economy, Clinical trial, London, University, Privacy, Bias, GM, Medical device

The event will offer unique insights into the world of synthetic data generation (SDG) and its transformative potential for healthcare.

Key Points: 
  • The event will offer unique insights into the world of synthetic data generation (SDG) and its transformative potential for healthcare.
  • SDG involves using generative AI to create synthetic data from real data while ensuring data privacy, security, and utility.
  • Previously held virtually, the Synthetic Data Summit 2023 is an in-person gathering for chief data officers, privacy professionals, data scientists, and healthcare insights directors interested in how this technology is addressing critical issues in healthcare data, such as data privacy, diversity and data bias, enabling more equitable clinical research, and data augmentation.
  • A number of life sciences companies will share their experiences using synthetic data in practice on real world data and clinical trial data.

Synthetic Data Summit 2023 highlights progress, practical applications, and potential of synthetic health data

Retrieved on: 
Thursday, October 19, 2023
Replica, United Kingdom, Synthetic data, SDG, SVP, Medicine, University of Ottawa, Summit, Aetion, Savoy Place, Canada Research Chair in International Political Economy, Clinical trial, London, University, Privacy, Bias, GM, Medical device

The event will offer unique insights into the world of synthetic data generation (SDG) and its transformative potential for healthcare.

Key Points: 
  • The event will offer unique insights into the world of synthetic data generation (SDG) and its transformative potential for healthcare.
  • SDG involves using generative AI to create synthetic data from real data while ensuring data privacy, security, and utility.
  • Previously held virtually, the Synthetic Data Summit 2023 is an in-person gathering for chief data officers, privacy professionals, data scientists, and healthcare insights directors interested in how this technology is addressing critical issues in healthcare data, such as data privacy, diversity and data bias, enabling more equitable clinical research, and data augmentation.
  • A number of life sciences companies will share their experiences using synthetic data in practice on real world data and clinical trial data.

From HITECH to the COVID-19 PHE: These Real-World Data Technologies are Helping Define Evidence-Based Care

Retrieved on: 
Wednesday, August 30, 2023
Real-World Evidence, Cosmos, Komodo, Real, Research report, Drug development, Procurement, Thermo Fisher Scientific, Real world evidence, COVID-19, RWD, Electronic health record, Health policy, Organization, Evidence, Aetion, Acquisition, RWE, Health Information Technology for Economic and Clinical Health Act, Carev Dvor, Ecosystem, Public health surveillance, Health information management, Pharmaceutical industry, IQVIA, Tempus, Research

'Real-world data' (RWD) has been used in a variety of research purposes to develop 'real-world evidence' (RWE) for decades, but never to the extent that is occurring today.

Key Points: 
  • 'Real-world data' (RWD) has been used in a variety of research purposes to develop 'real-world evidence' (RWE) for decades, but never to the extent that is occurring today.
  • However, nearly 80% of healthcare data is still in unstructured formats, necessitating specialized solutions that can help process this data so it can be applied effectively.
  • "By working together, they can overcome barriers such as data fragmentation, data quality concerns, and regulatory uncertainties.
  • The research is relevant to any healthcare stakeholder looking to leverage real-world data for evidence-based decision making.

Aetion® Publishes Screening Tool to Identify Candidate Programs for Using Real-World Evidence to Support Effectiveness Claims in FDA Applications in Peer-Reviewed Journal

Retrieved on: 
Friday, August 25, 2023
ECA, SPACE, Isabella Tree, Clinical Pharmacology & Therapeutics, SURF, Food and Drug Administration, RCT, RWD, Aetion, Evaluation, RWE, FDA, Eduardo Toda y Güell, Food, Medical device, Pharmaceutical industry, Agency

SURF intends to help sponsors make an initial feasibility assessment for using real-world data (RWD) to provide substantial evidence of effectiveness to support a U.S. Food and Drug Administration (FDA) approval.

Key Points: 
  • SURF intends to help sponsors make an initial feasibility assessment for using real-world data (RWD) to provide substantial evidence of effectiveness to support a U.S. Food and Drug Administration (FDA) approval.
  • In recent years, FDA has made considerable progress in advancing its RWE program.
  • "The SURF tool is based on Aetion's experience, and our review of FDA guidance and RWE uses in Agency approvals.
  • To learn more about how Aetion can support your business leaders with using RWE in regulatory applications, please visit https://www.aetion.com to request a meeting today.

Cognito Therapeutics Announces Poster Presentations at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2023 Meeting

Retrieved on: 
Monday, May 8, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Mental toughness, Partnership, Cognito, Health policy, ISPE, ISPOR, Deficit spending, Research, Pharmacoeconomics, MCI, CNS, Aetion, Patient, Risk, Amnesia, Diagnosis, AD, Therapy, Summit, International Society for Pharmacoepidemiology, International Society, Disease, Pharmaceutical industry

Cognito Therapeutics , a neurotechnology company advancing disease-modifying therapies to treat CNS diseases, announced today two poster presentations at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2023 Meeting, held May 7-10 in Boston, MA.

Key Points: 
  • Cognito Therapeutics , a neurotechnology company advancing disease-modifying therapies to treat CNS diseases, announced today two poster presentations at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2023 Meeting, held May 7-10 in Boston, MA.
  • The Summit is co-located with and being held immediately prior to the Society’s annual international conference, ISPOR 2023 .
  • The Summit is a collaboration between ISPOR, the International Society for Pharmacoepidemiology (ISPE), and the Duke-Margolis Center for Health Policy.
  • ISPOR is a leading professional society for health economics and outcomes research.